معرفی
L. Nathan Tumey serves as Associate Professor and Vice Chair in the Department of Pharmaceutical Sciences at Binghamton University's School of Pharmacy and Pharmaceutical Sciences, where he also holds the position of Assistant Graduate Director. With 15 years of prior pharmaceutical industry experience, he joined the university in 2017 to establish a research program focused on next-generation antibody-drug conjugates (ADCs) for cancer and autoimmune disorders.
His academic credentials include:
- BS from King University
- PhD in Chemistry from Duke University (2001) under Michael Pirrung
Tumey's research centers on ADC innovation, with specific expertise in bioconjugation chemistry, linker design, and immune-modulating payloads. Key projects include immune-stimulating antibody conjugates, glucocorticoid-antibody conjugates, legumain-cleavable linkers, and site-specific conjugation technology. His work bridges medicinal chemistry and therapeutic development for oncology and immunological diseases.
Analysis of his 15 most recent publications (2023-2025) reveals dominant themes in ADC technology advancement, particularly targeting strategies for rhabdomyosarcoma (via FGFR4) and acute myeloid leukemia (via CD123), alongside innovations in linker stability and payload delivery systems. His research consistently addresses translational challenges in ADC development.
Tumey actively collaborates with industry through scientific advisory board positions and consulting engagements with biotechnology and pharmaceutical companies. University news reports indicate he has secured research grants supporting his drug delivery technology initiatives and maintains partnerships to advance therapeutic development.
His laboratory on Binghamton University's campus operates at the intersection of pharmaceutical sciences and biomedical engineering, developing targeted delivery systems using advanced chemical and imaging techniques to address unmet medical needs in cancer and autoimmune disorders.
